<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310269</url>
  </required_header>
  <id_info>
    <org_study_id>CSOM230B2410</org_study_id>
    <nct_id>NCT02310269</nct_id>
  </id_info>
  <brief_title>Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease</brief_title>
  <official_title>Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, multinational, multi-center post-marketing study, to further
      document the safety and efficacy of pasireotide s.c. administered in routine clinical
      practice in patients with Cushing's disease. Patients with Cushing's disease and treated with
      pasireotide s.c. alone and in combination with other therapies will be monitored. For this
      study, each enrolled patient will be followed up for 3 years after enrollment. Patients who
      permanently discontinue pasireotide s.c. prior to completing the 3-year observation period
      will be followed up for 3 months after the last dose of pasireotide s.c.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2013</start_date>
  <completion_date type="Anticipated">May 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability profile of pasireotide s.c.</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Number of pasireotide s.c related adverse events and serious adverse events, when administered as monotherapy or in combination with other therapies in patients with Cushing's disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients that reach mean UFC ≤ ULN as short and long-term efficacy measure</measure>
    <time_frame>At 1, 3, 6, 12, 24 and 36 months after enrolling into the study</time_frame>
    <description>The proportion of patients with a mean UFC ≤ ULN at 1, 3, 6, 12, 24 and 36 months after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of mean UFC measures of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline of mean UFC measures of disease activity after enrolling into the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving serum cortisol Normalization of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Proportion of patients achieving serum cortisol Normalization of disease activity where normalization refers to being within the upper and lower limit of normal ranges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change of blood pressure from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change of blood pressure from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with favorable shift of blood pressure from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The proportion of patients with favorable shift of blood pressure from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in safety and efficacy parameters over a period of 3 months</measure>
    <time_frame>3 months after patient's discontinuation</time_frame>
    <description>Safety parameters include: Adverse events , Serious Adverse Events, vital signs, blood pressure, heart rate, body temperature, blood glucose (fasting plasma glucose, HemoglobinA1c), hormones (IGF-1, GH, TSH/free T4), liver enzymes (AST, ALT, alkaline phosphatase, γGT, total bilirubin), hematology, electrolytes, immunological events (e.g., allergic reactions: rash, pruritus, injection site reactions), gallbladder ultrasound and ECGs. Efficacy parameters include: Urinary Free Cortisol, serum cortisol, serum cortisol after dexamethasone testing, salivary cortisol, plasma ACTH, fasting serum lipid profile, Blood pressure, body weight, body mass index, waist circumference, tumor size and quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change in tumor size</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change in tumor size after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change from baseline in patient-reported outcome questionnaires</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline in patient -reported outcome questionnaires (Cushing QoL and EURO QoL) after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum cortisol measures of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline of serum cortisol measures of disease activity after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum cortisol after dexamathasone testing measures of disease activity</measure>
    <time_frame>3-year followup</time_frame>
    <description>The absolute and percentage change from baseline of serum cortisol after dexamathasone testing measures of disease activity after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of salivary cortisol measures of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline of salivary cortisol measures of disease activity after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of ACTH measures of disease activtity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline of ACTH measures of disease activity after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving serum cortisol after dexamethasone testing Normalization of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Proportion of patients achieving serum cortisol after dexamethasone testing Normalization of disease activity where normalization refers to being within the upper and lower limit of normal ranges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving salivary cortisol Normalization of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Proportion of patients achieving salivary cortisol of disease activity where normalization refers to being within the upper and lower limit of normal ranges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving ACTH Normalization of disease activity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>Proportion of patients achieving ACTH of disease activity where normalization refers to being within the upper and lower limit of normal ranges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of fasting serum lipid profile measures of disease activtity</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change from baseline of fasting serum lipid profile measures of disease activity after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change of body weight from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change of body weight from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change of body mass index from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change of body mass index from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute and percentage change of waist circumference from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The absolute and percentage change of waist circumference from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with favorable shift of body weight from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The proportion of patients with favorable shift of body weight from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with favorable shift of body mass index from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The proportion of patients with favorable shift of body mass index from baseline after enrolling into the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with favorable shift of waist circumference from baseline</measure>
    <time_frame>3-year follow-up</time_frame>
    <description>The proportion of patients with favorable shift of waist circumference from baseline after enrolling into the study</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cushings Disease</condition>
  <arm_group>
    <arm_group_label>Pasireotide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOM230</intervention_name>
    <arm_group_label>Pasireotide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will consist of male and female patients aged 18 years or older with
        a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an
        option and who are treated with pasireotide s.c.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 18 years or older with a diagnosis of Cushing's disease
             for whom surgery has failed or for whom surgery is not an option

          -  Patients must be treated with pasireotide s.c. started either at the first visit for
             this study or prior to study entry

        Exclusion Criteria:

          -  Patients with ectopic ACTH-dependent Cushing's syndrome

          -  Patients with adrenal Cushing's syndrome

          -  Patients with Pseudo Cushing's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital SC - SOM230B2410</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen J. Pulaski-Liebert</last_name>
      <phone>617-726-7473</phone>
      <email>kpulaski@partners.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Tritos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University SC - SOM230B2410</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Sykes</last_name>
      <phone>614-688-6885</phone>
      <email>christiane.sykes@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Lawrence Kirschner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Spiller</last_name>
      <phone>412-359-5143</phone>
      <email>kspiller@aghendo.com</email>
    </contact>
    <investigator>
      <last_name>Murray B Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Dept.ofSeattle Neuroscience(2)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beena Gangadharan</last_name>
      <phone>206-320-7115</phone>
      <email>Beena.Gangadharan@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Zachary Litvak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amiens cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cédex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Mande</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Priest en Jarez Cedex</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tg. Mures</city>
        <zip>540061</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's disease,</keyword>
  <keyword>pasireotide s.c.</keyword>
  <keyword>Signifor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pasireotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

